A variety of approaches, including antisense oligonucleotides, siRNA, ribozymes, immunotherapy, and small molecular weight inhibitors, are being tested in survivin targeting protocols with the goal of improving tumor treatment outcomes [21]. This evidence concerns the gene BIRC5 and neoplasm.